Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clarus Therapeutics Holdings, Inc.BLUW · Entity 126356 | Chief Financial Officer | December 15, 2020 | December 15, 2020 |
| Onconetix, Inc.BWV · Entity 8471 | Chief Financial Officer | May 09, 2023 | May 11, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clarus Therapeutics Holdings, Inc.
Report date December 15, 2020 · Filed December 15, 2020
This filing explicitly reported no securities owned.
Onconetix, Inc.
Report date May 09, 2023 · Filed May 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2023-05-09 transaction · row 1
1 source rowRow 1 · 2023-05-09 · Grant · Acquired 100,000 · Balance 100,000 F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2023 Filed May 11, 2023 21:21 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-23-038668 · ownership.xml · nonDerivative · entry 1 Garfield Jon · CIK 0001336751 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. Read SEC document |
| May 04, 2022 Filed May 27, 2022 10:46 UTC | Onconetix, Inc. BWV · Entity 8471 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0001213900-22-030003 · ownership.xml · derivative · entry 1 Garfield Jon · CIK 0001336751 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, par value $0.00001 per share · 100,000 shares Expires 2032-05-04 F1 · derivative.exercise_date: Stock options (the "Options") were granted to Mr. Garfield on May 4, 2022. The Options vest and become exercisable as follows: 25% of the Options will vest on September 15, 2022 and the remainder of the Options vest in equal monthly installments over the following 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.